Back to Trials
NCT06904287PHASE3Recruiting

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Wake Forest University Health Sciences

Start Date

12/16/2025

Completion Date

6/1/2027

Summary

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

Detailed Description

The purpose of this prospective, randomized, double-blinded study is to compare the relative efficacy and safety of intravenous magnesium in conjunction with intravenous prochlorperazine in the treatment of migraines. Participants will be patients presenting to the Emergency Department with primary diagnosis of migraine.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Age ≥ 18 years or older * Able to provide informed consent * English speaking * Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics Exclusion Criteria: * Pregnancy defined as a positive urine HCG * Allergy or sensitivity to study drug * Stated history of renal insufficiency * Documented history of myasthenia gravis * Consumption of study drug within 48 hours prior to enrollment * Previously enrolled in this trial during a different patient encounter

Interventions

DRUG

Magnesium

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Migraine

Locations

Advocate Christ Medical Center Emergency Department

Oak Lawn, Illinois 60453

United States